Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Nasdaq ends lower with tech; investors assess softer jobs data
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
Exact Sciences Reports Fourth Quarter and Full Year 2015 Results
February 24, 2016 6:00 AM ESTMADISON, Wis., Feb. 24, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company reported revenues of $39.4 million as a result of completing more than 104,000 Cologuard tests for full-year 2015. The company generated $14.4 million in revenues from approximately 38,000 completed Cologuard tests during the fourth quarter ended Dec. 31, 2015.
The cumulative number of physicians ordering Cologuard expanded steadily in 2015. During the fourth quarter of 2015 this total grew 27 percent from the third quarter to nearly 27,000 physicians. On average, approximately 500 new physicians ordered Cologuard each... More
